Summit Therapeutics is focused on developing innovative therapies for serious diseases, particularly in the areas of antibiotic resistance and genetic disorders. The company employs a proprietary platform known as Discuva, which is designed to discover and develop new antibiotics that can effectively target resistant bacteria. This technology leverages advanced microbiology and genomics to identify novel compounds, enabling the development of treatments that can overcome the challenges posed by antibiotic-resistant infections.

In addition to its antibiotic development efforts, Summit Therapeutics is also advancing its capabilities in the field of genetic medicine. The company is utilizing its proprietary technology, known as the "DMD" platform, to create therapies for Duchenne muscular dystrophy (DMD), a severe genetic disorder. This platform focuses on the development of utrophin modulators, which aim to restore the production of utrophin, a protein that can compensate for the lack of dystrophin in DMD patients. Through these technologies, Summit Therapeutics is committed to addressing unmet medical needs and improving patient outcomes in challenging therapeutic areas.

United States

Summit Therapeutics is a leader in antibiotic innovation.

Our new mechanism antibiotics are designed to become the new standards of care for the benefit of patients and create value for payors and healthcare providers.

We are currently developing new mechanism antibiotics for C. difficile infection and gonorrhoea and are using our proprietary Discuva Platform to expand our pipeline.

Cancer

Summit Therapeutics

Non-small cell lung carcinoma

Non-squamous cancers

Ivonescimab + chemotherapy

Squamous cancers

Ivonescimab (SMT112) 

Ivonescimab

Biliary Tract Cancer

Ivonescimab (SMT112) +Chemotherapy

Bacterial infection

Intestinal infection

<p class="font_7">Ridinilazole is an oral small molecule new mechanism antibiotic that is designed to selectively kill C. difficile, thereby preserving patients’ protective gut microbiome and leading to sustained CDI cures. In a Phase 2 proof of concept trial in CDI patients, ridinilazole showed statistical superiority in sustained clinical response ('SCR') rates compared to the standard of care, vancomycin. In that trial, SCR was defined as clinical cure at end of treatment and no recurrence of CDI within 30 days of the end of therapy. Ridinilazole was also shown to be highly preserving of the gut microbiome in the Phase 2 proof of concept trial, which was believed to be the reason for the improved clinical outcome for the ridinilazole-treated patients. In addition, ridinilazole preserved the gut microbiome to a greater extent than the marketed narrow-spectrum antibiotic fidaxomicin in an exploratory Phase 2 clinical trial. Ridinilazole has received Qualified Infectious Disease Product ('QIDP') designation and has been granted Fast Track designation by the US Food and Drug Administration. The QIDP incentives are provided through the US GAIN Act and include a potential extension of marketing exclusivity for an additional five years upon FDA approval.</p>

Summit Therapeutics

Company Details